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Abstract
Self-administration of factor and bypassing agents by persons with hemophilia in the home setting
is recommended to facilitate earlier intervention after bleeding episodes. The objective of this
review was to summarize recombinant activated coagulation factor VII (rFVIIa) safety and efficacy
data from clinical trials and patient registries documenting use in the home treatment setting in
people with congenital hemophilia with inhibitors (CHwI). A total of 16 studies and registries were
identified for inclusion; 14 evaluated on-demand treatment of acute bleeding episodes (865
patients, 9024 bleeding episodes) and 2 evaluated use for secondary prophylaxis (108 patients,
42,861 prophylaxis days). In the on-demand studies, efficacy was consistently high (81%-96%),
and thrombotic events were uncommon (n53). In the secondary prophylaxis studies, rFVIIa was
associated with a 45% to 59% reduction in bleeding episodes and no thrombotic events. These
data support the clinical practice of administering rFVIIa in patients in the home treatment setting
after initiation under a physician’s care.
1 | INTRODUCTION
The management of congenital hemophilia in the home treatment setting
is common and is advocated by current treatment guidelines, which, in
light of the many potential advantages of home treatment relative to
administration in treatment centers, recommend its use “where appropri-
ate and possible.”1 This practice may facilitate earlier initiation of therapy
after bleed onset, resulting in more rapid recovery from bleeding as well
as reduced pain, dysfunction, emergency department visits, hospitaliza-
tions, long-term disability, and costs.2–7 Self-administration of replace-
ment clotting factor products in the home setting may also facilitate
earlier initiation of routine prophylaxis, which may reduce the risk of
developing arthropathy and thereby improve long-term musculoskeletal
outcomes.8,9 Moreover, patients may experience improvements in health-
related quality of life because of greater freedoms accompanied by home
treatment.10 However, clotting factor replacement may be complicated
by the development of inhibitors, where even high doses of clotting factor
replacement products may be insufficient to prevent or control bleeding,
requiring use of alternative “bypassing” agents for management.
Recombinant activated coagulation factor VII (rFVIIa, NovoSeven®
RT, Novo Nordisk A/S, Bagsværd, Denmark) is a highly purified
recombinant protein11 that is approved for the treatment of bleeding
episodes and the prevention of bleeding during surgery or invasive pro-
cedures in adults and children with congenital hemophilia with inhibitors
(CHwI) as well as other congenital and acquired bleeding disorders.12
The clinical use of rFVIIa in patients with CHwI is supported by a wealth
of data spanning nearly 30 years.13,14 Current prescribing information
stipulates that treatment should be initiated under the direction of a
qualified health care professional and provides patient instructions for
reconstitution and administration.12
The rFVIIa formulation is well-suited for home use. It is room-
temperature stable, and thus does not require refrigeration when
temperatures do not exceed 258C (778F).12,15 It retains its activity and
stability for extended periods after reconstitution (for 6 hours at 258C
[778F] and for 24 hours at 58C [418F]).16 Current US prescribing infor-
mation recommends administration within 3 hours after reconstitu-
tion.12 The rFVIIa injection is of low volume (1–8 mL, depending
on the dose) and can be administered rapidly (over a period of
940 | VC 2017Wiley Periodicals, Inc. wileyonlinelibrary.com/journal/ajh Am J Hematol. 2017;92:940–945.
Received: 26 January 2017 | Revised: 26 May 2017 | Accepted: 1 June 2017
DOI: 10.1002/ajh.24811
AJH
2–5 minutes).12,17,18 These attributes enhance the ease of rFVIIa use
and would be expected to facilitate self-administration at home. Many
patients who received rFVIIa in clinical trials and patient registries were
treated in the home setting. This review aims to summarize efficacy
and safety (thromboembolic events) data from Novo Nordisk clinical
trials and patient registries that evaluated rFVIIa home treatment in
people with CHwI.
2 | METHODS
2.1 | Clinical data sources
Studies evaluating the efficacy and safety of rFVIIa for the manage-
ment of CHwI (bleed treatment and perioperative management
[approved indications in the US]12 and secondary prophylaxis [investi-
gational use in the US]) in the home setting were identified through a
search of the clinical trials database. Both clinical trials (phases 1
through 4) and patient registries (prospective and retrospective) were
considered for inclusion. Combinations of clinical trial reports and pub-
lications were used as data sources. These sources included both pub-
lished and unpublished (data on file, Novo Nordisk) data that have
been included in periodic safety updates to regulatory authorities.
2.2 | Efficacy outcomes
Reported efficacy rates from the individual studies were extracted and
efficacy definitions were recorded (Table 1).
2.3 | Safety outcomes
All reports of thromboembolic events (TEs) were recorded. Adverse
events other than TEs were not included in the current review. Safety
reporting requirements particularly in post-approval safety studies
(PASS) are different for studies conducted in Japan, and specifically dif-
ferences in reporting of all adverse events irrespective of relationship
to product compared with PASS focus on adverse drug reactions possi-
bly/probably related to products.
2.4 | Statistical methodology
All data were summarized; no statistical analyses were performed.
3 | RESULTS
A total of 16 studies evaluating rFVIIa home use were identified (Figure
1). Fourteen of these studies assessed on-demand use (for the treatment
of bleeding episodes) and 2 evaluated use for the prevention of bleeding
in patients with established joint disease (secondary prophylaxis).
3.1 | On-demand treatment studies
A total of 793 patients were treated for 8758 bleeding episodes in
the on-demand treatment studies (three phase 2 trials, two phase 3
trials, and nine phase 4 registries; Table 1). Both standard doses
(90 mcg/kg) and high single doses (270 mcg/kg) were represented.
Dosing in observational studies was variable (at the discretion of the
prescribing physician). No attempt to differentiate efficacy based on
dosing regimen was made for the purpose of this review. Efficacy
was consistently high across the 12 on-demand treatment studies
for which efficacy outcomes were reported (691 patients; 7543
bleeding episodes). Using typical response criteria (which included
the evaluation of bleeding, and in some studies, consideration of the
need for additional hemostatic agents; see Table 1 for description of
efficacy), rFVIIa provided effective hemostasis in 81% to 96% of the
bleeding episodes.
Safety data were reported as part of the protocols as primary or
secondary endpoints. For the current review, only the rates of TEs for
all bleeding episodes in the 14 studies were extracted (perioperative
management entered on bleeding episode forms was included in one
registry).19 Overall, TEs were rare. A total of 3 events were identified in
8758 episodes (0.034%), 2 in a single 10-year Japanese postmarketing
study20: 1 visual field defect with suspected cerebral infarction and 1
central venous occlusion. No further information is available about
these two events. The third (thrombus of the arteriovenous fistula
leading to study withdrawal) was in the adeptTM2 trial, which compared
vatreptacog alfa with rFVIIa.21 In trials and registries where full safety
information about the events including causality was available the
overall thrombotic rate was 1/7040 bleeds (0.014%).
3.2 | Secondary prophylaxis studies
A total of 108 patients were treated with rFVIIa for a total of
42,861 treatment days in the 2 secondary prophylaxis studies (one
phase 2 and one phase 4; Table 2). Dosing in the phase 2 prospec-
tive study (22 patients, 1885 prophylaxis days) was 90 mcg/kg or
270 mcg/kg daily.22 Dosing in the phase 4 retrospective study (86
patients, 40 976 treatment days) varied and often changed over
time.23 Efficacy was evaluated as the frequency of bleeds during
the prophylaxis period compared with the frequency of bleeds dur-
ing a pre-prophylaxis period, and in both studies prophylaxis vs.
pre-prophylaxis was associated with reductions in bleeding fre-
quency. In the phase 2 study, efficacy was evaluated as the number
of bleeds per month during the 3-month prophylaxis period com-
pared with the 3-month pre-prophylaxis period. Bleeding frequency
in this study was reduced by 45% with the 90 mcg/kg dose (n511)
and 59% with the 270 mcg/kg dose (n511; both P< .0001 vs. the
pre-prophylaxis period).22 In the phase 4 study where the period of
prophylaxis depended on retrospective review of available medical
records (range, 22 to 3651 days), bleeding frequency was reduced
by 46% (95% CI, 254.0 to 238.2) for the total bleeding population
(n574; defined as patients with at least 1 bleed during the pre-
prophylaxis period [12/86 patients were excluded from the analysis
of change in bleed rate because they had no bleeds during the pre-
prophylaxis period]) and 52% (95% CI, 260.7 to 243.3) for the fre-
quent bleeding population subset (n536; defined as patients hav-
ing at least 1 bleed per month during the pre-prophylaxis period).23
There were no TEs reported in either of these studies. 22,23
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TABLE 1 On-demand treatment of bleeding with rFVIIa
Trial ID Year
Trial phase/
type
Number
of patients
Number of
bleeding
episodes Dose
Efficacy rate
and definition Safety
F7HAEM-
151033,34,a
2002–2004 2
Double-blind
22 42 270 mcg/kg 3 1 or
90 mcg/kg 3 3
88% controlled without
the need for additional
hemostatic agents
No TEs
F7HAEM-
206835,36,a
2001–2006 2
Double-blind
24 45 270 mcg/kg 3 1 or
90 mcg/kg 3 3
91%-92% achieved he-
mostasis within 9 hours
of first dose of rFVIIa
without the use of res-
cue medication
No TEs
NN7128–1907
(Pioneer 1)37
2009–2011 2
Double-blind
23 359 Varied per local standard
practice
84%b No TEs
F7HT/USA/1/
USA (US Home
TRx)2
NA 3
Open-label
56 877 90 mcg/kg (1–3 doses); indivi-
dualized based on weight
92% achieved hemosta-
sis or experienced sig-
nificantly decreased
bleeding
No TEs
NN1731–3562
(adeptTM2)21
2011–2012 3
Double-blind
57 227 90 mcg/kg (1–3 doses) 93% received no addi-
tional hemostatic medi-
cation within 12 hours
after the first rFVIIa dose
1 TE
HRS/HTRS
Registry38
2000–2002 4
Registry
42 793 Varied (<100 mcg/kg/dose,
27%; 100–150 mcg/kg/dose,
28%; 150–200 mcg/kg, 25%;
or >200 mcg/kg, 21%)
87% achieved complete
hemostatic control with-
in 72 hours
No TEs
HTRS Registry19 2004–2008 4
Registry
129 2041 Varied (range, 38–400 mcg/
kg/infusion)
89%-93% achieved he-
mostasis
No TEs
F7HAEM-1965
(DOSE)39
2008–2009 4
Observational
35 158 Varied (range, 30 mcg/kg/dose
to 400 mcg/kg/dose)
Not assessed (diaries) No TEs
F7HAEM-3507
(ONE)40
2008–2010 4
Registry
102 496 Varied (stratified by initial
dose: low [120 mcg/kg],
31%; intermediate [>120 to
<250 mcg/kg], 26%; or high
[250 mcg/kg], 43%)
85%-96% achieved
complete or partial he-
mostasis (self-reported)
within 9 hours after first
injection
No TEs
NN7025–3061
(SMART-7)41,42
2010–2015 4
Observational
51 592 Varied (median 277.8, mean
569.5)
91.3% No TEs
F7HAEM-3537
(UKHCDO Regis-
try)43,44
2008–2011 4
Registry
67f 1057f Varied (CHwI initial dose: 90
mcg/kg, 16%; >90 to <180
mcg/kg, 35%; 180 to <270
mcg/kg, 18%; 270 mcg/kg,
10%)
Not reported (diaries) No TEs
F7HAEM-
194720,31,45,a
1999–2010 4
Observational
144c 1718c N/Ae 88% 2 TEsd
F7HAEM-1921
(WIRK Registry)46
2008–2010 4
Registry
14 269 Varied (mean initial dose,
150.5 mcg/kg)
90% experienced
complete hemostasis or
significantly reduced
bleeding within 9 hours
after initiating treatment
No TEs
F7HAEM-385047,a 2010–2012 4
Observational
27 84 Varied (initial dose: 120 mcg/
kg, 55%; >120 to <250 mcg/
kg, 12%; 250 mcg/kg, 33%)
88% home treated No TEs
Total 793 8758 3 TEs
Abbreviations: HRS, Hemophilia Research Society; HTRS, Hemophilia and Thrombosis Research Society; NA, not available; rFVIIa, recombinant acti-
vated coagulation factor VII; TE, thromboembolic event; UKHCDO, United Kingdom Centre Doctors’ Organisation.
aUnpublished data.
bEfficacy included 3 response grades: excellent, good, and moderate.
cPatients with evaluable efficacy.
dOne visual field defect with suspected cerebral infarction, one central venous occlusion.
eInformation limited to one abstract in English and citations to that abstract.
fOut of a total of 139 patients and 1356 episodes across all indicated diagnoses.
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4 | DISCUSSION
The current review provides a summary of evidence regarding the effi-
cacy and safety of rFVIIa in the home treatment setting. The rate of
efficacy for the on-demand treatment of acute bleeding episodes
across 12 studies and registries comprising 7543 bleeding episodes
was high (84%-96%) and TEs were uncommon (n53). Administration
for secondary prophylaxis in 2 studies/registries (43 000 prophylaxis
days), was associated with a 45%-59% reduction in bleeding episodes
and no TEs.
The high rate of efficacy described herein is consistent with the
range of efficacy reported in registration trials (71%-93%),12,24–27
which comprised both patients treated at home and patients who
received rFVIIa at hemophilia treatment centers. These findings sug-
gest that patients who opt to self-administer rFVIIa at home or at their
location may experience efficacy similar to what they would expect if
rFVIIa were administered at a hemophilia treatment center in early clin-
ical studies. Furthermore, treatment at home may facilitate more timely
administration,2,3 and thus more rapid recovery.
The low rate of TEs is also consistent with previous observations.
The current US prescribing information indicates that 0.2% of bleeding
episodes in patients with CHwI in clinical trials were complicated by
TEs.12 Rates of TEs reported in previously published cumulative
reviews of safety in both clinical trials and clinical use (postmarketing
surveillance, registries, regulatory sources, and investigator-initiated tri-
als) are similarly low (<0.004%).28–31 There were a total of 25 TEs
among 700 000 standard dose infusions in patients with CHwI or
acquired hemophilia who received rFVIIa between licensure in 1996
and April 2003;29 30 TEs among 800 000 standard dose infusions in
patients with CHwI or acquired hemophilia who received rFVIIa
between May 2003 and December 2006;30 and no recorded TEs
among 2000 bleeding episodes in patients with CHwI who received
rFVIIa between 2004 and 2008.28 In a recent safety update of data
from post-marketing sources, observational studies, registries, sponta-
neous reporting, and literature cases comprising an estimated 4 million
standard doses of rFVIIa used across all approved indications between
1996 and 2013, 138 TEs were reported in patients with CHwI or
acquired hemophilia.31
The results of this review must be interpreted in light of certain
limitations. First, the data were derived from multiple studies and regis-
tries that used varied regimens and response criteria and had differing
patient populations; there was no single established and validated
means for assessment of efficacy. Thus, efficacy as defined in this
review encompasses a range of responses, including the extent and
duration of bleeding as well as the need for additional hemostatic
agents. Additionally, whereas the inclusion of patient registries allowed
for a larger set of patient data, the less rigorous (uncontrolled) nature
of registries versus clinical studies should be noted. Furthermore,
FIGURE 1 Patients identified in studies of rFVIIa treatment of congenital hemophilia with inhibitors in a home setting
TABLE 2 Secondary prophylaxis with rFVIIa
Trial ID Year Trial phase/type
Number of
patients
Number of
prophylaxis days Dose Efficacy Safety
F7HAEM-150522,32 2004–2005 2/Double-blind 22 1885 90 mcg/kg or
270 mcg/kg
45%-59% reduction No TEs
F7HAEM-3695
(PRO-PACT)23
2009–2010 4/Observational 86 40 976 Varied 46%-52% reduction No TEs
Total 108 42 861 0 TEs
rFVIIa, recombinant activated coagulation factor VII; TE, thromboembolic event.
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combination of data from different dosing regimens prevents drawing
conclusions about the relative efficacy of these dosing strategies. Second,
not all the studies included were specifically designed to assess treatment
in the home setting, one in which the assessment of efficacy remains
challenging and relies on patient and/or caregiver reporting and the
extent to which they communicate with the study center in determining
treatment (greater for phase 2–3 studies than phase 4 observational
registries). However, the primary assessment in this review is around
safety, and the inclusion in registries of what is most often a required
affirmation about presence/absence of adverse reactions associated with
treatment minimizes the risk of underreporting of safety events.
Many potential areas for future research remain. Mitigating the
development of arthropathy and disability remains a key goal for
hemophilia treatment; thus, the impact of home treatment on these
long-term outcomes should be assessed. Effects on quality of life
should also be further explored. Hoots and colleagues (2008)32 con-
cluded that secondary prophylaxis with rFVIIa (which was self-
administered in the home setting22) may improve health-related quality
of life in frequently bleeding patients who have CHwI. Observed
improvements included significantly reduced bleeding-related hospital-
izations and school or work absences as well as a trend towards
reduced pain and enhanced mobility.32 These improvements would be
expected to reduce costs relative to administration at treatment cen-
ters; however, such cost comparisons remain to be performed. Finally,
the identification of any demographic or clinical characteristics associ-
ated with beneficial outcomes could aid the identification of patients
most likely to benefit from home treatment.
In conclusion, this review of data from Novo Nordisk clinical trials
and patient registries supports the safety and efficacy of rFVIIa when
self-administered or administered by a trained caregiver in the home
treatment setting. Extensive registry data confirm the findings of clini-
cal trials and support that rFVIIa can be used under the direction of
qualified health care professionals by patients and caregivers trained to
infuse at home or the patient’s location rapidly after the onset of a
bleed to maximize the chances for a rapid and successful resolution of
the episode, or to routinely infuse to prevent bleeding when so
directed by a health care professional.
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